Complete Summary

GUIDELINE TITLE

Cervical cytology screening.

BIBLIOGRAPHIC SOURCE(S)


GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Cervical cancer

GUIDELINE CATEGORY

Screening

CLINICAL SPECIALTY

Internal Medicine
Obstetrics and Gynecology
Oncology
Pathology
Pediatrics
INTENDED USERS

Health Care Providers
Physicians

GUIDELINE OBJECTIVE(S)

- To aid practitioners in making decisions about appropriate obstetric and gynecologic care
- To provide a review of the best available evidence on screening for cervical cancer

TARGET POPULATION

Sexually active women and adolescent girls

INTERVENTIONS AND PRACTICES CONSIDERED

1. Cervical cytology screening
2. Timing of initial screening and frequency of screening
3. Standard versus liquid-based thin layer preparation
4. Concomitant human papillomavirus testing

MAJOR OUTCOMES CONSIDERED

- Sensitivity and specificity of screening
- Incidence of cervical cancer

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1985 and May 2003. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles.
NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

**I**: Evidence obtained from at least one properly designed randomized controlled trial.

**II-1**: Evidence obtained from well-designed controlled trials without randomization.

**II-2**: Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.

**II-3**: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.

**III**: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses
Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Analysis of available evidence was given priority in formulating recommendations. When reliable research was not available, expert opinions from obstetrician–gynecologists were used. See also the "Rating Scheme for the Strength of Recommendations" field regarding Grade C recommendations.

3 of 10
RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

**Level A** — Recommendations are based on good and consistent scientific evidence.

**Level B** — Recommendations are based on limited or inconsistent scientific evidence.

**Level C** — Recommendations are based primarily on consensus and expert opinion.

COST ANALYSIS

Any woman aged 30 years or older who receives negative test results on both cervical cytology screening and human papillomavirus deoxyribonucleic acid (HPV DNA) testing should be rescreeened no more frequently than every 3 years. The combined use of these modalities has been shown to increase sensitivity but also decrease specificity and increase cost. However, it has been estimated that the increase in screening interval will offset the cost of this new screening regimen.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Practice Bulletins are validated by two internal clinical review panels composed of practicing obstetrician-gynecologists generalists and sub-specialists. The final guidelines are also reviewed and approved by the American College of Obstetricians and Gynecologists (ACOG) Executive Board.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The grades of evidence (I-III) and levels of recommendation (A-C) are defined at the end of the "Major Recommendations" field.

The following recommendations are based on good and consistent scientific evidence (Level A):

- Annual cervical cytology screening should begin approximately 3 years after initiation of sexual intercourse, but no later than age 21 years.
- Women younger than 30 years should undergo annual cervical cytology screening.
- Women aged 30 years and older who have had three consecutive negative cervical cytology screening test results and who have no history of cervical
intraepithelial neoplasia (CIN) grade 2 or CIN 3, are not immunocompromised and are not HIV infected, and were not exposed to diethylstilbestrol in utero may extend the interval between cervical cytology examinations to every 2 to 3 years.

- Evidence-based data indicate both liquid-based and conventional methods of cervical cytology are acceptable for screening.
- Women who have undergone hysterectomy with removal of the cervix for benign indications and who have no prior history of CIN 2 or CIN 3 or worse may discontinue routine cytology testing.

The following recommendations are based on limited and inconsistent scientific evidence (Level B):

- Women previously treated for CIN 2 or CIN 3 who have completed their posttreatment follow-up should be monitored annually until at least three consecutive negative cytology screening results are documented.
- The use of a combination of cervical cytology and human papillomavirus (HPV) deoxyribonucleic acid (DNA) screening is appropriate for women aged 30 years and older. If this combination is used, women who receive negative results on both tests should be rescreened no more frequently than every 3 years.
- Women who have undergone hysterectomy with removal of the cervix and have a history of CIN 2 or CIN 3 should continue to be screened annually until three consecutive negative vaginal cytology test results are achieved.

The following recommendations are based primarily on consensus and expert opinion (Level C):

- Physicians should consider individualization in determining the time to begin screening, the interval between cervical cytology examinations, the age at which cervical cytology testing is no longer needed, and the testing methodology to be used. In addition to considering risk factors for cervical cancer, the provider ideally should be able to determine the patient's past screening history and reliably monitor the patient in the future.
- Evidence is inconclusive to establish an upper age limit for cervical cancer screening. If screening is discontinued, risk factors should be assessed during the annual examination to determine if reinitiating screening is appropriate.
- Yearly testing using cytology alone remains an acceptable screening plan.
- Regardless of the frequency of cervical cytology screening, women should be counseled that annual examinations, including pelvic examination, are still recommended.

Definitions:

Grades of Evidence

I: Evidence obtained from at least one properly designed randomized controlled trial.

II-1: Evidence obtained from well-designed controlled trials without randomization.
**II-2**: Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.

**II-3**: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.

**III**: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

**Levels of Recommendations**

**Level A** — Recommendations are based on good and consistent scientific evidence.

**Level B** — Recommendations are based on limited or inconsistent scientific evidence.

**Level C** — Recommendations are based primarily on consensus and expert opinion.

**CLINICAL ALGORITHM(S)**

None provided

**EVIDENCE SUPPORTING THE RECOMMENDATIONS**

**TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

**BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

**POTENTIAL BENEFITS**

Appropriate screening for cervical cancer

**POTENTIAL HARMs**

False-positive test results can lead to unnecessary evaluation and treatment. False-negative results lead to undetected cervical cancer and associated morbidity and mortality.

**QUALIFYING STATEMENTS**

None provided
These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Foreign Language Translations  
Patient Resources

For information about availability, see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Staying Healthy

IOM DOMAIN

Effectiveness  
Patient-centeredness  
Timeliness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)


ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2003 Aug

GUIDELINE DEVELOPER(S)
American College of Obstetricians and Gynecologists - Medical Specialty Society

SOURCE(S) OF FUNDING

American College of Obstetricians and Gynecologists (ACOG)

GUIDE LINE COMMITTEE

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Gynecology

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Not stated

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDE LINE STATUS

This is the current release of the guideline.

GUIDE LINE AVAILABILITY

Electronic copies: None available

Print copies: Available for purchase from the American College of Obstetricians and Gynecologists (ACOG) Distribution Center, PO Box 4500, Kearneysville, WV 25430-4500; telephone, 800-762-2264, ext. 192; e-mail: sales@acog.org. The ACOG Bookstore is available online at the ACOG Web site.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

The following are available:
